Your browser is no longer supported. Please, upgrade your browser.
Settings
BCEL [NASD]
Atreca, Inc.
Index- P/E- EPS (ttm)-2.70 Insider Own1.20% Shs Outstand36.84M Perf Week6.95%
Market Cap277.57M Forward P/E- EPS next Y-2.79 Insider Trans-13.64% Shs Float22.47M Perf Month5.54%
Income-91.70M PEG- EPS next Q-0.69 Inst Own93.30% Short Float29.07% Perf Quarter-41.73%
Sales- P/S- EPS this Y-12.10% Inst Trans1.50% Short Ratio18.25 Perf Half Y-46.00%
Book/sh6.01 P/B1.46 EPS next Y1.40% ROA-37.70% Target Price- Perf Year-62.60%
Cash/sh6.69 P/C1.31 EPS next 5Y- ROE-41.70% 52W Range7.68 - 25.03 Perf YTD-45.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-64.38% Beta-
Dividend %- Quick Ratio12.00 Sales past 5Y- Gross Margin- 52W Low16.08% ATR0.65
Employees134 Current Ratio12.00 Sales Q/Q- Oper. Margin- RSI (14)47.37 Volatility7.11% 7.01%
OptionableYes Debt/Eq0.00 EPS Q/Q4.00% Profit Margin- Rel Volume2.24 Prev Close8.77
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume357.99K Price8.91
Recom1.50 SMA20-1.07% SMA50-10.12% SMA200-35.88% Volume75,104 Change1.65%
Jun-04-21Resumed Robert W. Baird Outperform $30 → $27
Feb-08-21Initiated Jefferies Buy $30
Apr-22-20Initiated Wedbush Outperform $27
Apr-22-20Initiated H.C. Wainwright Buy $30
Apr-16-20Initiated Robert W. Baird Outperform $30
Sep-04-19Initiated ROTH Capital Buy $30
Jul-15-19Initiated Stifel Buy $28
Jul-15-19Initiated Evercore ISI Outperform
Jul-15-19Initiated Cowen Outperform
Jul-15-19Initiated Canaccord Genuity Buy $23
Jun-07-21 08:38PM  
May-14-21 08:30AM  
May-13-21 07:30AM  
Apr-06-21 04:30PM  
Mar-10-21 04:30PM  
Feb-25-21 04:05PM  
Feb-22-21 04:30PM  
Feb-11-21 11:58PM  
Dec-12-20 03:12PM  
Nov-14-20 07:39AM  
Nov-12-20 08:30AM  
Nov-06-20 08:30AM  
Oct-16-20 11:01AM  
Oct-14-20 04:30PM  
Sep-13-20 09:54AM  
Sep-03-20 08:00AM  
Aug-31-20 12:00PM  
Aug-12-20 08:30AM  
Aug-05-20 04:30PM  
Jul-16-20 12:06AM  
Jul-15-20 04:01PM  
12:00PM  
Jul-08-20 08:01AM  
08:01AM  
Jun-22-20 11:46AM  
Jun-15-20 07:31AM  
Jun-11-20 08:00AM  
May-21-20 08:00AM  
May-14-20 04:30PM  
May-13-20 05:00PM  
May-12-20 04:30PM  
Apr-06-20 04:30PM  
Mar-12-20 05:33PM  
Mar-11-20 04:30PM  
Feb-24-20 04:30PM  
Feb-13-20 04:30PM  
Feb-05-20 04:05PM  
Dec-26-19 10:48AM  
Dec-19-19 04:54PM  
Dec-03-19 08:00AM  
Nov-14-19 08:00AM  
Nov-12-19 04:05PM  
Nov-05-19 08:00AM  
Sep-19-19 09:19AM  
Aug-26-19 04:05PM  
Aug-17-19 07:30AM  
Aug-13-19 04:05PM  
Jul-15-19 02:22PM  
Jul-11-19 08:00AM  
Jun-20-19 11:16AM  
Jun-19-19 09:40PM  
08:20AM  
Jun-17-19 10:07AM  
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenberg Norman MichaelChief Scientific OfficerMar 17Option Exercise4.815,00024,0502,916Mar 19 07:52 PM
Greenberg Norman MichaelChief Scientific OfficerMar 17Sale16.735,00083,6500Mar 19 07:52 PM
Robinson William HewittDirectorMar 15Sale16.895,00084,450368,948Mar 16 05:45 PM
Serafini TitoChief Strategy OfficerMar 11Sale18.3110,000183,130353,875Mar 15 07:09 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 17Option Exercise5.165,00025,8005,000Feb 19 07:56 PM
Greenberg Norman MichaelChief Scientific OfficerFeb 17Sale18.955,00094,7520Feb 19 07:56 PM
Robinson William HewittDirectorFeb 16Sale19.075,00095,330373,948Feb 18 09:55 PM
Serafini TitoChief Strategy OfficerFeb 11Sale18.9310,000189,272363,875Feb 16 05:31 PM
Greenberg Norman MichaelChief Scientific OfficerJan 19Option Exercise5.165,00025,8005,000Jan 21 07:04 PM
Greenberg Norman MichaelChief Scientific OfficerJan 19Sale15.215,00076,0440Jan 21 07:04 PM
Robinson William HewittDirectorJan 14Sale15.062,25934,011378,948Jan 15 08:59 PM
Robinson William HewittDirectorJan 13Sale15.052,74141,239381,207Jan 15 08:59 PM
Serafini TitoChief Strategy OfficerJan 11Sale15.0210,000150,192373,875Jan 13 05:14 PM
Greenberg Norman MichaelChief Scientific OfficerDec 17Option Exercise4.565,00022,8005,000Dec 21 06:48 PM
Greenberg Norman MichaelChief Scientific OfficerDec 17Sale16.615,00083,0510Dec 21 06:48 PM
Robinson William HewittDirectorDec 14Sale16.675,00083,369383,948Dec 15 07:47 PM
Serafini TitoChief Strategy OfficerDec 11Sale15.8710,000158,735383,875Dec 15 05:16 PM
Greenberg Norman MichaelChief Scientific OfficerNov 27Option Exercise4.563,17514,4783,175Dec 01 05:06 PM
Greenberg Norman MichaelChief Scientific OfficerNov 27Sale15.343,17548,7190Dec 01 05:06 PM
Greenberg Norman MichaelChief Scientific OfficerNov 17Option Exercise4.561,8258,3221,825Nov 18 05:25 PM
Greenberg Norman MichaelChief Scientific OfficerNov 17Sale15.041,82527,4480Nov 18 05:25 PM
Robinson William HewittDirectorNov 16Sale15.005,00075,000388,948Nov 17 06:30 PM
Serafini TitoChief Strategy OfficerNov 16Sale15.128,847133,784393,875Nov 17 06:28 PM
Serafini TitoChief Strategy OfficerNov 11Sale15.101,15317,407399,067Nov 13 06:16 PM
Greenberg Norman MichaelChief Scientific OfficerNov 10Option Exercise4.564,50020,5204,500Nov 12 05:08 PM
Greenberg Norman MichaelChief Scientific OfficerNov 10Sale15.104,50067,9630Nov 12 05:08 PM
Greenberg Norman MichaelChief Scientific OfficerOct 19Option Exercise4.565002,280500Oct 21 05:32 PM
Greenberg Norman MichaelChief Scientific OfficerOct 19Sale15.125007,5620Oct 21 05:32 PM
Robinson William HewittDirectorOct 13Sale15.715,00078,530393,948Oct 16 04:01 PM
Serafini TitoChief Strategy OfficerOct 12Sale15.0010,000150,000400,220Oct 13 07:29 PM
Serafini TitoChief Strategy OfficerOct 06Sale15.051,21818,334410,220Oct 08 05:16 PM
Robinson William HewittDirectorSep 18Sale15.045,00075,188398,948Sep 22 06:18 PM
Serafini TitoChief Strategy OfficerSep 18Sale15.118,782132,664411,438Sep 22 06:17 PM
Robinson William HewittDirectorAug 14Sale15.005,00075,000403,948Aug 17 08:26 PM
Serafini TitoChief Strategy OfficerAug 14Sale15.0010,000150,000420,220Aug 17 08:22 PM
Robinson William HewittDirectorJul 13Sale20.235,000101,139408,948Jul 15 09:46 PM
Serafini TitoChief Strategy OfficerJul 13Sale20.2010,000202,018430,220Jul 15 09:45 PM
Greenberg Norman MichaelChief Scientific OfficerJul 01Option Exercise4.5610,27246,84010,272Jul 06 06:02 PM
Greenberg Norman MichaelChief Scientific OfficerJul 01Sale21.8310,272224,2240Jul 06 06:02 PM